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Abstract 
BACKGROUND: Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for 
blood cancers; but results in the development of graft-versus-host disease (GVHD) in up to 70% of 
recipients. During GVHD, tissue damage results in ATP release into the extracellular compartment 
activating P2X7 on antigen-presenting cells, leading to the release of pro-inflammatory cytokines and 
subsequent activation of donor T cells. Therefore, the aim of the present study was to examine murine 
(m) P2rx7 and human (h) P2RX7 gene expression in GVHD target organs of humanised mice, and further 
characterise disease impact in these organs. METHODS: NOD-scid IL2Rγnull (NSG) mice were injected 
with human peripheral blood mononuclear cells (hu-PBMC-NSG mice) or phosphate-buffered saline (PBS, 
control). Leucocytes were assessed by flow cytometry; gene expression was measured by quantitative 
polymerase chain reaction (qPCR), and tissue sections examined by histology. RESULTS: Compared with 
control mice, hu-PBMC-NSG mice had increased mP2rx7 and mP2rx4 expression in the duodenum, ileum 
and skin. hP2RX7 was expressed in all tissues examined. hu-PBMC-NSG mice also displayed increased 
mReg3g expression in the duodenum and ileum, despite limited histological gut GVHD. hu-PBMC-NSG 
mice showed histological evidence of GVHD in the skin, liver and lung. Compared with control mice, hu-
PBMC-NSG mice displayed increased ear swelling. CONCLUSION: Combined data revealed that P2rx7 is 
up-regulated in gut and skin GVHD and that P2RX7 is present in target tissues of GVHD, corresponding to 
human leucocyte infiltration. Data also reveal increased mReg3g expression and ear swelling in hu-PBMC-
NSG mice, offering new measurements of early-stage gut GVHD and skin GVHD, respectively. 
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Background: Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative 
therapy for blood cancers; but results in the development of graft-versus-host disease 
(GVHD) in up to 70% of recipients. During GVHD, tissue damage results in the release of 
ATP into the extracellular compartment activating P2X7 on antigen presenting cells, leading 
to the release of pro-inflammatory cytokines and subsequent activation of donor T cells. 
Therefore, the aim of this study was to examine murine (m) P2rx7 and human (h) P2RX7 
gene expression in GVHD target organs of humanised mice, and further characterise disease 
impact in these organs. Methods: NOD-scid IL2Rγnull (NSG) mice were injected with human 
peripheral blood mononuclear cells (hu-PBMC-NSG mice) or PBS (control). Leukocytes 
were assessed by flow cytometry; gene expression was measured by qPCR, and tissue 
sections examined by histology. Results: Compared to control mice, hu-PBMC-NSG mice 
had increased mP2rx7 and mP2rx4 expression in the duodenum, ileum and skin. hP2RX7 
was expressed in all tissues examined. hu-PBMC-NSG mice also displayed increased 
mReg3g expression in the duodenum and ileum, despite limited histological gut GVHD. hu-
PBMC-NSG mice showed histological evidence of GVHD in the skin, liver and lung. 
Compared to control mice, hu-PBMC-NSG mice displayed increased ear swelling. 
Conclusion: Combined this data reveals that P2rx7 is upregulated in gut and skin GVHD and 
that P2RX7 is present in target tissues of GVHD, corresponding to human leukocyte 
infiltration. Data also reveals increased mReg3g expression and ear swelling in hu-PBMC-







Allogeneic haematopoietic stem cell transplantation (HSCT) is a common curative therapy 
for multiple haematological disorders, including blood cancers (1). Acute graft-versus-host 
disease (GVHD) is a potentially lethal complication that arises following HSCT, damaging 
the gut, skin, liver and lung (2). Acute GVHD occurs in up to 70% of HSCT recipients with a 
mortality rate of 20% (3). GVHD is mediated by donor immune cells, which initiate a 
massive inflammatory response in host organs (4). GVHD develops when host antigen 
presenting cells activate donor T cells (5). These donor T cells are then directed to target 
organs by homing molecules including integrin β7 (6) and cutaneous lymphocyte antigen 
(CLA) (7), which direct inflammatory cells to the gut and skin, respectively. Activated donor 
T cells release pro-inflammatory cytokines such as interferon gamma (IFNγ) (8), propagating 
a positive feedback loop leading to further activation of donor T cells, and increased tissue 
damage (9).  
The gut is  affected in approximately 62% of GVHD cases and is a major cause of mortality 
(10). Gut damage arises when donor T cells cause severe inflammation in the intestines, 
leading to crypt cell degeneration and destruction of the villous epithelium (11). Plasma 
regenerating islet-derived 3 (REG3)α has emerged as a clinical biomarker of GVHD 
progression in humans (12). Likewise, mRNA for REG3γ, the murine homologue of REG3α, 
is upregulated in villous enterocytes of mice with GVHD, corresponding to increased 
circulating REG3γ in these mice (13).  
The skin is affected in approximately 80% of GVHD cases, and is usually the first tissue to 
show clinical signs of damage (14). Whilst this damage does not typically result in mortality, 
it causes significant pain to patients (15). The liver is affected in approximately 50% of 
GVHD cases, and is a major cause of mortality (16). Liver damage occurs when leukocytes 
infiltrate the area surrounding the portal vein; leading to hepatocyte death and bile duct 
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destruction (17). In the lung, GVHD presents mainly as an idiopathic pneumonia syndrome, 
with little to no cell apoptosis (2). 
Allogenic mouse models are commonly used to study GVHD and have provided significant 
insight into the understanding of this disease (18), but they do not fully replicate GVHD in 
humans. As such, humanised mouse models of GVHD have been developed to further 
elucidate the role of human immune cells in this disease. Common examples of these models 
involve the injection of human peripheral blood mononuclear cells (hPBMCs) into immune 
deficient mice, such as NOD-scid IL-2Rγnull (NSG) (19) or NOD-scid IL-2Rγmutant (NOG) 
(20) mice. Humanised mouse studies of GVHD often report disease involvement in the liver, 
but involvement of the gut, skin or lungs are not always reported (19, 21-23). Homing 
molecules on donor T-cells have shown importance in both humans receiving allogeneic 
HSCT (6, 7) and allogeneic mouse models (24), however they have not been extensively 
examined in humanised NSG or NOG mice.  
Purinergic receptors, including the ATP-gated P2X7 receptor, play an important roles in 
controlling T cell-mediated inflammation following allogeneic transplantation (25, 26). P2X7 
blockade delays allograft rejection in both islet (27) and cardiac (28) transplantation in mice, 
which corresponded with reduced Th1 and Th17 cells and inflammation in both transplanted 
tissues. Whilst a naturally occurring mutation in human P2X7 leads to excessive Th17 cell 
generation and poorer outcomes in patients following cardiac transplantation (29). Moreover, 
P2X7 blockade can also reduce allograft rejection in both lung (30) and skin (31) 
transplantation in mice, again corresponding with reduced inflammation in both transplanted 
tissues. 
The ATP/P2X7 signalling axis also plays important roles following HSCT. In allogeneic 
mouse models of GVHD, resulting tissue damage leads to the release of danger associated 
molecular patterns such as ATP (32). Subsequently, this extracellular ATP activates P2X7 on 
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antigen presenting cells to promote donor T cell activation (32). Human (h) P2RX7 and 
mouse (m) P2rx7 gene expression has been shown to be respectively increased in human 
patients with GVHD and in mouse models of this disease (32), but analysis of P2RX7 
expression in GVHD remains limited. The importance of P2X7 activation in mediating 
GVHD progression has been shown in allogeneic models of this disease (32, 33) and more 
recently by us in a humanised NSG model of GVHD (34-36). Collectively, this highlights the 
need for a more thorough analysis of P2RX7 expression in GVHD target organs. 
The current study aimed to examine mP2rx7 and hP2RX7 expression in GVHD target organs 
of humanised NSG mice and to further characterise disease impact in these organs. 
Humanised NSG mice (hu-PBMC-NSG) had increased mP2rx7 expression in the duodenum, 
ileum and skin, but not the liver, lung, spleen or other areas of the gut. hP2RX7 was 
expressed in all tissues examined. Human leukocytes expressing integrin β7 were present in 
the blood and spleens of hu-PBMC-NSG mice, while mReg3g gene expression was increased 
in the duodenum and ileum of hu-PBMC-NSG mice despite limited histological gut GVHD. 
CLA expressing human leukocytes were present in hu-PBMC-NSG mice, with mice 
displaying histological evidence of cutaneous GVHD and increased ear swelling. Both the 







Human peripheral blood mononuclear cell isolation 
Human blood was acquired and used as approved by the University of Wollongong Human 
Ethics Committee (Wollongong, Australia). Whole blood was collected from healthy 
Caucasian donors (one female and six males, aged 21-40 years) into VACUETTE® lithium 
heparin tubes (Greiner Bio-One, Frickenhausen, Germany) with informed written consent 
from all donors. Whole blood was mixed with an equal volume of Dulbecco’s modified 
phosphate-buffered saline (PBS) (Thermo Fisher Scientific, Waltham, MA, USA), under laid 
with Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden), and centrifuged at 560xg for 30 
min. PBMCs were collected, washed twice with PBS and resuspended at the indicated 
concentrations in PBS. 
Humanised murine model of graft-versus-host disease 
All animal procedures were carried out as approved by the University of Wollongong Animal 
Ethics Committee (Wollongong, Australia) within the Rodent Research Facility of the 
University of Wollongong. Female NOD-scid IL-2Rγnull (NSG) mice (aged 5-6 weeks) were 
obtained from Australian BioResources (Moss Vale, Australia) and housed in ventilated 
cages (Techniplast, Buggugiate, Italy) with a 12h light/12h dark cycle, and provided with 
autoclaved food and water provided ad libitum. Mice were acclimitised for 1 week before 
GVHD was initiated as described (23). Briefly, 10 x 106 human PBMCs (from two male and 
two female healthy Caucasian donors, aged 21-40 years) were injected intra-peritoneally 
(i.p.) into NSG mice (hu-PBMC-NSG mice). Control mice were injected i.p. with an equal 
volume of PBS. Mice were monitored for signs of GVHD three times a week from day 0 until 
endpoint using a clinical scoring system as described (37). Ear thickness was measured three 
times a week using Interapid spring-loaded callipers (Rolle, Switzerland). Engraftment was 
assessed via immunophenotyping of tail vein blood at 3 weeks post-injection. At endpoint all 
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mice were euthanased by slow-fill carbon dioxide, and blood, spleen, duodenum, jejunum, 
ileum, colon, liver, lung, skin and ear were removed from mice. The gastrointestinal tract 
(stomach to rectum) was removed whole and measured to determine total gut, small intestine 
and large intestine length. 
Antibodies 
Peridinin chlorophyll protein complex (PerCP)-conjugated anti-mouse CD45 (clone 30-F11; 
1:20 dilution), fluorescein isothiocyanate (FITC)-conjugated anti-human CD45 (clone HI130; 
1:20 dilution), allophycocyanin (APC)-conjugated anti-human CD3 (clone UCHTI; 1:20), R-
phycoerythrin (PE)-conjugated anti-human CD4 (clone SK3; 1:20 dilution), PE-cyanine 7 
(PE-Cy7)-conjugated anti-human CD8 (clone RPA-T8; 1:50 dilution), Brilliant Violet (BV) 
421-conjugated anti-human β7 (clone FIB504; 1:20 dilution), and BV605-conjugated anti-
human CLA (clone FIB504; 1:20 dilution) monoclonal antibodies (mAb) were obtained from 
BD (San Jose, CA, USA). 
Flow cytometry 
Freshly isolated hPBMCs were obtained as outlined above. At 3 weeks post-injection, tail 
vein blood from mice was collected into citrate solution (Sigma-Aldrich, St Louis, MO, 
USA), diluted with PBS and centrifuged (300xg, 5 min). Spleens were manually 
homogenised in PBS, passed through a 70 µm nylon filter (Falcon Biosciences, New York, 
NY, USA) and centrifuged (300xg, 5 min). Livers were diced then digested in RPMI-1640 
medium (Life Technologies, Carlsbad, CA, USA) containing 4 mg/mL DNase I (Roche, 
Basel, Switzerland) and 7 mg/mL collagenase (Sigma-Aldrich) (37oC, 45 min), filtered 
through a 70 µm nylon filter and centrifuged (300xg, 5 min). Blood, spleen and liver samples 
were treated with ammonium chloride potassium lysis buffer (150 mM NH4Cl, 1 mM 
KHCO3, 0.1 mM Na2CO3) for 5 min, to remove red blood cells, and washed once with PBS 
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(300xg, 5 min). hPBMCs or mouse samples (blood, spleen, and liver) were resuspended at 1 
x 106 cells/mL in PBS containing 2% foetal calf serum (Bovogen, Keilor East, Australia) and 
centrifuged (300xg, 5 min). Samples (1 x 106 cells per tube) were incubated with 
fluorochrome-conjugated mAb in the dark (ice, 15 min). Cells were washed once with PBS 
(300xg, 3 min), resuspended in PBS and events were acquired using a BD LSR Fortessa X-20 
flow cytometer (BD). Proportions of leukocyte subsets were determined using FlowJo 
software version 8.7.1 (BD). Single cells were first gated by forward scatter-height and -
width, and second by forward and side scatter -height as described (37), and then as indicated 
in figures. 
Histological analysis 
Tissues from mice were treated with neutral buffered (10%) formalin (Sigma-Aldrich) for 24-
48 hours, before being processed and set in paraffin wax. Samples were sectioned (3-5 µm) 
and stained with haematoxylin and eosin (POCD, Artarmon, Australia). Samples were 
reviewed in consultation with a histopathologist. All samples were then examined for 
histological damage, in a blinded fashion, using a Leica DMRB microscope (Leica, Wetzlar, 
Germany). All tissues were observed for immune cell infiltrates. Intestinal sections were 
examined for signs of crypt apoptosis and crypt degeneration. Livers were examined for bile 
duct degradation. Skin and ear were examined to identify apoptotic cells, epidermal 
thickening and separation at the dermal-epidermal junction.  
RNA isolation and cDNA synthesis 
Tissues from mice were stored in RNAlater (Sigma-Aldrich) at -20oC until required. RNA 
was isolated from duodenum, jejunum, ileum, colon, liver, spleen and lung using TRIzol 
reagent (Thermo Fisher Scientific) as per manufacturer's instructions. Flank skin and whole 
ear samples were homogenised with a Precellys 24 tissue homogeniser (Bertin Instruments, 
9 
 
Montigny-le-Bretonneux, France) as described (38) and RNA was isolated using the 
ISOLATE II RNA Mini Kit (Bioline, London, UK) as per manufacturer’s instructions. cDNA 
was synthesised from RNA using the qScript cDNA Synthesis Kit (Quanta Biosciences, 
Beverly, MA, USA) as per manufacturer’s instructions.  
Quantitative polymerase chain reactions (qPCR) 
Relative gene expression was determined using TaqMan Universal Master Mix II (Thermo 
Fisher Scientific) as per the manufacturer’s instructions. qPCR was conducted with FAM-
labelled- mP2rx7 (Mm01199503_m1), hP2RX7 (Hs00175721_m1), hP2RX7B (custom, For: 
‘5GGAAAATGGTTTGGAGAAGGAAGTG3', Rev: 
5'CGATGAGGAAGTCGATGAACACA3') mP2rx1 (Mm01251971_g1), mP2rx4 
(Mm00501790_g1), mReg3g (Mm01181783_g1), mIl22 (Mm01226722_g1) or hIL22 
(Hs01574154_m1) (Thermo Fisher Scientific), using either VIC-labelled mGapdh 
(Mm99999915_g1) or hHPRT1 (Hs99999909_m1) as the housekeeping gene (Thermo Fisher 
Scientific). Amplifications were conducted on a QuantStudio 5 (Thermo Fisher Scientific) 
with triplicate reactions for each sample and gene. Data was analysed using QuantStudio 
Design and Analysis Software 1.4.0 (Thermo Fisher Scientific). Gene expression was 
quantified using the ΔΔCt method and made relative to expression in either the duodenum 
(mP2rx1, mP2rx4 and mReg3g) or spleen (mP2rx7) of a control mouse, or a hu-PBMC-NSG 
mouse spleen (hP2RX7 and hP2RX7B). Primer efficiency was determined by the generation 
of a standard curve using serial dilutions of cDNA. 
Enzyme-linked immunosorbent assays (ELISA) 
Whole blood was collected via cardiac puncture, incubated (room temperature, 30 min) and 
centrifuged (1700xg, 5 min). Serum was collected and stored at -80oC until required. Serum 
REG3γ was measured with a Murine REG3γ ELISA kit (MyBioSource San Diego, CA, 
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USA) as per the manufacturer’s instructions. Serum hIFNγ was measured with a Human 
IFNγ ELISA Kit (Life Technologies) as per the manufacturer’s instructions. 
Data presentation and statistical analysis 
All data is given as mean ± standard deviation unless otherwise stated. All statistical analyses 
were conducted using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA). 
Statistical differences were calculated using a student’s t test for single comparisons or one-
way analysis of variance (ANOVA) with a Tukey’s post-hoc test for multiple comparisons. 





NSG mice injected with hPBMCs contain circulating human T cells and develop clinical 
GVHD  
NSG mice typically develop GVHD following hPBMC injection and engraftment (19). In the 
current study NSG mice were injected i.p. with either 10 x 106 hPBMCs (hu-PBMC-NSG) or 
PBS (control). Tail vein blood was collected from all mice at 3 weeks post-injection, and 
analysed by flow cytometry (Figure 1a). As expected, control mice lacked hCD45+ cells, 
whilst hu-PBMC-NSG mice engrafted hCD45+ cells (Figure 1b), the majority of which were 
hCD3+ T cells (Figure 1c). Further analysis of the hCD3+ T cell population revealed similar 
proportions of hCD4+ or hCD8+ subtypes (Figure 1d).  
The above mice were monitored for up to 10 weeks. Weight change was similar between hu-
PBMC-NSG and control mice until week 3, at which time hu-PBMC-NSG mice steadily lost 
weight (Figure 1e). hu-PBMC-NSG mice developed significant signs of disease from 3 
weeks post-hPBMC injection, with significantly increased clinical score over time compared 
to control mice (Figure 1f). As a result, hu-PBMC-NSG mice had significantly reduced 
survival compared to control mice over 10 weeks, with the majority of hu-PBMC-NSG mice 
succumbing to disease by 10 weeks, whilst all control mice remained alive during this time 
(Figure 1g). The median survival time of hu-PBMC-NSG mice was 37.5 days. Collectively, 
these data reveal that following injection of hPBMCs, NSG mice engraft hCD4+ and hCD8+ 
T cells and develop signs of clinical GVHD from 3 weeks. 
hu-PBMC-NSG mice engraft hCD45+ hCD3+ T cells in the spleen and display 
circulating hIFNγ  
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Spleens from control and hu-PBMC-NSG mice at endpoint were examined by flow 
cytometry (Figure 2a). As above, control mice lacked hCD45+ cells, whilst hu-PBMC-NSG 
mice contained hCD45+ cells (Figure 2b); the majority of which were hCD3+ T cells (Figure 
2c). In contrast to the data at 3 weeks, the hCD3+ T cell population contained a significantly 
greater proportion of hCD4+ T cells than hCD8+ T cells (Figure 2d).  
P2X7 activation has an emerging role in GVHD in hu-PBMC-NSG mice (34-36). qPCR 
analysis of spleens from control and hu-PBMC-NSG mice demonstrated similar expression 
of mP2rx7 (Figure 2e). Moreover, qPCR revealed the presence of hP2RX7 in the spleens of 
hu-PBMC-NSG mice, as well as the presence of hP2RX7B (Figure 2f), an isoform associated 
with lymphocyte proliferation (39). The human housekeeping gene (hHPRT1), hP2RX7 and 
hP2RX7B were not detected in control mice, despite detection of mGapdh in these same 
samples (data not shown). 
Human IFNγ is produced by human T cells and has been shown to play important roles in 
GVHD development (8). Thus, hIFNγ concentrations in sera from endpoint mice were 
assessed by ELISA. hIFNγ was detected in all hu-PBMC-NSG mice, but no control mice  
tested (Figure 2g). Combined, these data indicate that hu-PBMC-NSG mice display a greater 
proportion of hCD4+ T cells compared to hCD8+ T cells, and express both mP2rx7 and 
hP2RX7 in the spleen, and have circulating human IFNγ. 
hu-PBMC-NSG mice engraft gut-homing T cells but do not develop histological signs of 
gut GVHD  
The gastrointestinal tract is a major target of GVHD (2). Thus, the current study aimed to 
characterise gut GVHD in hu-PBMC-NSG mice. Integrin β7 is an important homing 
molecule that directs various T cell subsets to the gut, and has been linked to GVHD 
progression (6). To first assess the presence of integrin β7 on circulating T cells, PBMCs 
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were isolated from the blood of seven healthy donors and integrin β7 expression on CD4+ or 
CD8+ T cell subsets examined by flow cytometry. Integrin β7 was expressed on the majority 
of CD4+ T cells, but a significantly smaller proportion of CD8+ T cells (Figure 3a). Next, 
integrin β7 expressing T cells were then examined in hu-PBMC-NSG mice. Again, integrin 
β7 was expressed on the majority of hCD4+ T cells and a significantly smaller proportion of 
hCD8+ T cells in the blood of hu-PBMC-NSG mice at 3 weeks post-hPBMC injection 
(Figure 3b), and in the spleens of these mice at endpoint (Figure 3c).  
Tissue from the duodenum, jejunum, ileum and colon were collected from mice at endpoint, 
stained with haematoxylin and eosin, and examined for signs of histological GVHD. There 
was limited evidence of histological GVHD throughout the gut of hu-PBMC-NSG mice with 
mild immune cell infiltration, no crypt degeneration and few apoptotic bodies (Figure 3d). 
As expected, guts of control mice displayed normal histology (Figure 3d). Of note, there was 
no evidence of diarrhoea from hu-PBMC-NSG mice (results not shown), as occasionally 
reported in other mouse models of GVHD (18). Thus, hu-PBMC-NSG mice engraft gut-
homing T cells but display limited evidence of histological gut GVHD. 
mP2rx7 and mReg3g expression are upregulated in the duodenum and ileum of hu-
PBMC-NSG mice, while gut length is unaltered 
It was hypothesised that shortened gut length may serve as an indicator of gastrointestinal 
GVHD as evidenced in inflammatory bowel disease in humans and mice (40, 41). Following 
euthanasia the gastrointestinal tracts were removed from control and hu-PBMC-NSG mice 
and the lengths of the lower gastrointestinal tract (duodenum to colon inclusive), small 
intestine and large intestine were measured. There was no significant difference in the lengths 
of the lower gastrointestinal tract, small intestine or large intestine between hu-PBMC-NSG 
and control mice (Figure 4a).  
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Despite limited changes in gut histology or length between mouse groups, qPCR analysis 
revealed that mP2rx7 was significantly upregulated in the duodenum and ileum, but not 
jejunum or colon, of hu-PBMC-NSG mice compared to control mice (Figure 4b). In contrast, 
hP2RX7 and hP2RX7B expression in each of these regions of the gut was limited, with no 
significant differences between sites or isoforms (Figure 4c). 
To determine if the increased expression of mP2rx7 in the duodenum and ileum observed 
above corresponded to changes in other P2X receptors commonly expressed on murine 
leukocytes (42, 43) associated with GVHD (44, 45), mP2rx1 and mP2rx4 in these tissues was 
assessed by qPCR. There was no difference in mP2rx1 expression in either the duodenum or 
ileum between hu-PBMC-NSG and control mice (Figure 4d). In contrast, mP2rx4 was 
significantly increased in the duodenum and partly increased in the ileum (albeit not 
significantly) of hu-PBMC-NSG mice compared to control mice (Figure 4e). 
With limited histological evidence of GVHD in the gut, the current study sought to determine 
if molecular signs of gut GVHD were present. REG3α is a clinical biomarker of human gut 
GVHD (12), whilst the murine homologue, REG3γ, is increased in the gut and serum of mice 
with allogeneic GVHD (13). Therefore, relative mReg3g expression was measured in control 
and hu-PBMC-NSG mice by qPCR. mReg3g expression in the duodenum and ileum, but not 
jejunum and colon, was significantly increased in hu-PBMC-NSG mice compared to control 
mice (Figure 4f). ELISA measurements revealed that there was no significant difference in 
serum REG3γ concentrations between hu-PBMC-NSG mice and control mice (Figure 4g). 
Notably, seven (47%) hu-PBMC-NSG mice had REG3γ concentrations greater than two 
standard deviations above the control mean, whilst three (20%) hu-PBMC-NSG mice had 
REG3γ concentrations two standard deviations below the control mean. 
Since IL-22 can regulate REG3γ and is involved in the pathogenesis of various gut disorders 
(46) including GVHD (47), the expression of mIl22 and hIL22 in duodenum and ileum, 
15 
 
tissues in which mReg3g expression was found to be significantly increased in hu-PBMC-
NSG mice above, were assessed by qPCR. mIl22 was not detected in duodenum or ileum 
from control or hu-PBMC-NSG mice (n = 4 and n = 8, respectively; data not shown). Whilst, 
hIL22 was only detected in the duodenum of one of 8 hu-PBMC-NSG mice (data not shown). 
Collectively, these data reveal that mP2rx7 and mReg3g are upregulated in the duodenum 
and ileum of hu-PBMC-NSG mice, and that these changes correspond to increases in mP2rx4 
expression but not mP2rx1, mIl22 or hIL22 expression. 
hu-PBMC-NSG mice engraft skin-homing T cells and develop cutaneous GVHD, 
including ear swelling 
The skin is a major target of GVHD and a leading cause of morbidity in HSCT recipients 
(14). Thus, the current study aimed to characterise cutaneous GVHD in hu-PBMC-NSG 
mice. Cutaneous lymphocyte antigen (CLA) is an important skin homing molecule for T 
cells, which has been linked to cutaneous GVHD (7). To assess the presence of CLA on 
circulating T cells, PBMCs were isolated from the blood of seven healthy donors and CLA 
expression on CD4+ or CD8+ T cell subsets examined by flow cytometry. CLA was present 
on approximately half of the CD4+ T cells, but near absent on CD8+ T cells (Figure 5a). 
Next, CLA expressing T cells were examined in hu-PBMC-NSG mice. Compared to PBMCs 
directly isolated from human blood, hCD4+ and hCD8+ T cells in the blood of hu-PBMC-
NSG mice at 3 weeks post-hPBMC injection displayed high proportions of CLA+ T cells, 
with significantly higher proportions of CLA+ hCD4+ T cells compared to CLA+ hCD8+ T 
cells (Figure 5b). In contrast, there was no difference in the proportions of hCD4+ or hCD8+ 
T cells expressing CLA in the spleens of these mice at endpoint (Figure 5c).  
Flank skin and ears from endpoint mice were collected and examined for evidence of 
histological GVHD. Both the flank skin and ears of hu-PBMC-NSG mice displayed signs of 
histological GVHD, with the presence of apoptotic bodies, epidermal hyperplasia 
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(thickening) and separation of the dermal-epidermal junction (Figure 5d). As expected, 
control mice did not display histological evidence of GVHD (Figure 5d). 
Measurements of ear swelling have long been used as an assay of cutaneous inflammation 
(48), but to our knowledge, this assay has not been used to assess GVHD in mice. As such, 
ear thickness, as a measure of ear swelling, was assessed thrice weekly in control and hu-
PBMC-NSG mice over 10 weeks. Mean ear thickness in control mice remained unchanged 
over this time (Figure 5e). In contrast, mean ear thickness in hu-PBMC-NSG mice increased 
from week 3, reaching a maximum plateau by week 6 and was significantly increased 
compared to that of control mice (Figure 5e).  
qPCR analysis revealed mP2rx7 expression was significantly upregulated  in the flank skin of 
hu-PBMC-NSG mice compared to control mice (Figure 5f). In contrast, mP2rx7 expression 
was decreased in the ears of hu-PBMC-NSG mice compared to control mice, although this 
difference failed to reach statistical significance due to one outlier in the hu-PBMC-NSG 
group (Figure 5f). qPCR analysis also revealed that both hP2RX7 and hP2RX7B were 
expressed in the flank skin and ears of hu-PBMC-NSG mice, with no significant differences 
between sites or isoforms (Figure 5g). 
As for gut tissues above, mP2rx1 and mP2rx4 expression in the flank skin of mice was 
analysed by qPCR. Similar to the duodenum and ileum, there was no difference in mP2rx1 
expression in flank skin between the two groups (Figure 5h), but mP2rx4 expression was 
significantly increased in this tissue from hu-PBMC-NSG mice compared to control mice 
(Figure 5i). Thus, hu-PBMC-NSG mice engraft skin homing T cells and develop cutaneous 
GVHD, corresponding to increases in both mP2rx7 and mP2rx4 but not mP2rx1 expression, 
or the expression of hP2RX7 in the skin. 
hu-PBMC-NSG mice develop hepatic GVHD with human T cells present in the liver 
17 
 
The liver is another major target of GVHD (16). Thus, the current study examined hepatic 
GVHD in hu-PBMC-NSG mice. Histological analysis revealed that hu-PBMC-NSG mice 
showed increased immune cell infiltration of the liver compared to control mice, and early 
signs of bile duct destruction (Figure 6a). King et al (19) demonstrated that hCD45+ cells 
were present in the livers of humanised mice. The current study confirmed, and expanded 
upon, this finding by showing the presence of hCD45+ cells in digested livers by flow 
cytometry, the majority of which were hCD3+ T cells (Figure 6b). qPCR analysis revealed 
similar mP2rx7 expression in the livers of hu-PBMC-NSG and control mice (Figure 6c). 
Moreover, both hP2RX7 and hP2RX7B were expressed in the livers of hu-PBMC-NSG mice, 
with no difference between isoforms (Figure 6d). Thus, hu-PBMC-NSG mice develop 
hepatic GVHD, corresponding with the presence of human T cells and hP2RX7 expression, 
but not changes in mP2rx7 expression, in the liver. 
hu-PBMC-NSG mice develop histological evidence of lung GVHD 
Previous studies have reported involvement of the lung in hu-PBMC-NSG mice (19). 
Therefore, the current study examined pulmonary GVHD in hu-PBMC-NSG mice. 
Histological analysis revealed increased immune cell infiltration into the lungs of hu-PBMC-
NSG mice compared to those of control mice (Figure 7a). qPCR analysis revealed similar 
mP2rx7 expression in the lungs of both control and hu-PBMC-NSG mice (Figure 7b). 
Moreover, both hP2RX7 and hP2RX7B were expressed in the lungs of hu-PBMC-NSG mice, 
with no difference between isoforms (Figure 7c). Thus, hu-PBMC-NSG mice develop 




The current study aimed to examine mP2rx7 and hP2RX7 expression in GVHD target organs 
of humanised mice, and further characterise disease impact in these organs. In this study, 
injection of hPBMCs into NSG mice resulted in the development of GVHD with clinical 
signs increasing over time, and weight loss commencing from week 3. The rate of disease 
progression was slower in the current study compared to other studies which involved the 
same injection regime of hPBMCs (19, 49). This difference is presumably due to the absence 
of irradiation in the present study, compared to pre-transplant irradiation used in these former 
studies. In contrast, disease progression was similar to previous works from our group in 
which mice were not irradiated (23, 34-37). The current study also confirmed the engraftment 
of human leukocytes, predominately CD4+ and CD8+ T cells. Engraftment of human 
leukocytes was similar to previous studies of irradiated and non-irradiated mice which 
demonstrated that hCD45+ cells make up between 40-80% of the leukocyte population, and 
that the majority of these cells are hCD3+ (19, 23, 34-37, 49). Furthermore, the current study 
further confirmed that the proportion of CD4+ T cells is greater than that of CD8+ T cells at 
endpoint, similar to previous studies from our group (23, 34-37) and others (19, 49). 
The current study examined the expression of mP2rx7, hP2RX7 and hP2RX7B in GVHD 
target tissues of control and hu-PBMC-NSG mice. mP2rx7 tended to be higher in hu-PBMC-
NSG mice compared to control mice but such increases only reached statistical significance 
in the duodenum, ileum and skin. These increases in mP2rx7 expression in the duodenum and 
skin, and to a lesser extent the ileum, corresponded to increases in mP2rx4, but not mP2rx1 
expression. This suggests that the increases in mP2rx7 expression in these tissues may be due 
to the infiltration of macrophages, which co-express both P2X7 and P2X4 (43). Notably, 
mP2rx7 expression in the ear was an exception to the above tissues with gene expression 
decreased. Whether this reflects a compensatory mechanism or possible changes in ear 
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cartilage, which also express P2X7 (50), remains unknown. hP2RX7 and hP2RX7B 
expression was also observed in all examined tissues. Given the expression of hP2X7 on T 
cells (51) and other human leukocytes (37), this indicates that human leukocytes were present 
in these tissues from most mice. Finally, it should be noted that relative mP2rx7 expression in 
tissues from NSG mice closely resembles hP2RX7 expression profiles seen in humans (52), 
with greatest expression in the skin, followed by the lungs, spleen, liver and gut. 
Although flow cytometric analyses in hu-PBMC-NSG mice in former studies (19, 23, 34-37, 
49) is extensive, the histological analysis of GVHD tissues in each is limited. The current 
study provides the broadest tissue analysis of this model to date, including analysis of four 
regions of the gut; duodenum, jejunum, ileum and colon. Previous studies have reported 
blunting of villi (53) and lymphocyte infiltration of intestinal crypts (19, 53). In contrast to 
previous studies (19, 53), and despite the presence of potential gut-homing integrin β7+ 
human T cells, histological evidence of gut GVHD was limited in hu-PBMC-NSG mice in 
the current study. Recent evidence suggests that radiation plays a large role in controlling 
gut-homing T cells in allogeneic models of GVHD (54). Furthermore, NSG mice, and other 
strains encoding the IL-2Rγnull mutation, show reduced T cell trafficking and infiltration into 
the gastrointestinal tract (55). Thus, the absence of irradiation in the current model and 
defects in gut homing in NSG mice provides an explanation for the limited gut GVHD 
observed in the current study.  
Despite limited evidence of histological gut GVHD, the current study provided molecular 
evidence of gut GVHD with increased mReg3g expression in the duodenum and ileum. These 
increases did not correspond to an increase in mIl22 or the presence of hIL22, which were 
largely absent in these tissues, suggesting that up-regulation of mReg3g expression in hu-
PBMC-NSG mice may be IL-22-independent. Of note, the increase in mReg3g in the gut 
regions paralleled increases in mP2rx7, suggesting these regions may be more susceptible to 
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GVHD. Moreover, there was an increased trend in serum REG3γ consistent with gut GVHD. 
However, serum REG3γ was increased in only some hu-PBMC-NSG mice and failed to 
correlate with integrin β7+ human T cells or the limited histological damage (data not shown). 
Increases in serum REG3α/REG3γ concentrations are thought to be due to damage of the 
mucosal epithelial cells (12). However, given that some hu-PBMC-NSG mice displayed 
relatively high concentrations of REG3γ compared to control mice, this may suggest that this 
antimicrobial peptide may also enter circulation in the absence of epithelial cell damage. 
The current study also provides the most thorough analysis of cutaneous GVHD in hu-
PBMC-NSG mice. King et al (19) originally reported minimal histological GVHD 
involvement in the skin of humanised mice; however more recent studies reported 
lymphocyte infiltration in the skin of such mice (34, 49). Consistent with these previous 
findings, the current study identified extensive lymphocyte infiltration and signs of apoptosis 
in flank skin of hu-PBMC-NSG mice. This was further expanded by observing the same 
histological signs of cutaneous GVHD in the ears of these mice. GVHD damage in the ears 
was also consistent with increases in ear swelling over time, shown for the first time in any 
mouse model of GVHD. Changes in ear thickness provide a quantitative method for 
determining cutaneous GVHD in mouse models and could be used alongside traditional 
clinical measures such as scaling of skin and fur loss. Although the proportions of CLA+ T 
cells did not correlate with histological evidence of GVHD or ear swelling (results not 
shown), others have shown that these cells home to the skin of hu-PBMC-NSG mice (49).  
The present study revealed histological evidence of hepatic GVHD in hu-PBMC-NSG mice 
consistent with previous findings (19, 34). We also demonstrated that a large proportion of 
leukocytes in the liver were of human origin consistent with King et al (19).  This was further 
expanded with the current study demonstrating that the majority of these human leukocytes 
were T cells, as similarly seen in the spleens of hu-PBMC-NSG mice. Of note, our previous 
21 
 
studies have revealed that activation of P2X7 plays an important role in hepatic GVHD in hu-
PBMC-NSG mice (35, 36), but despite this the expression of mP2rx7 was similar between 
hu-PBMC-NSG and control mice. This may suggest activation of P2X7 to mediate hepatic 
GVHD in this model may be regulated by P2X7 present elsewhere in these mice.  
Finally, the current study revealed that lungs are also a target in this hu-PBMC-NSG model 
of GVHD. Lung involvement following HSCT is used to diagnose chronic GVHD (56), 
however lung involvement has also been reported in patients with acute GVHD (57). Similar 
to the current study, previous allogeneic (58) and humanised (19, 22) mouse studies have 
reported immune cell infiltration in the lungs of mice with GVHD. Therefore, even though 
the lung is involved, hu-PBMC-NSG mice can still be considered a model of acute GVHD. 
In conclusion, this study demonstrated that mP2rx7 expression was increased in the 
duodenum, ileum and skin of hu-PBMC-NSG mice supporting a role for P2X7 in these 
organs. hP2RX7 is present in target tissues of GVHD, consistent with human leukocyte 
infiltration into these tissues. The present study also demonstrated that the skin, liver and lung 
are highly involved in this model, with limited histological gut involvement. Finally, 
increased mReg3g expression and ear swelling in hu-PBMC-NSG mice offer potential 











• P2X7 plays an important role in GVHD but expression has not been characterised in 
disease tissues in humanised mouse models of GVHD, and disease impact in these 
tissues is oftentimes not reported 
• Hu-PBMC-NSG mice have increased mP2rx7 and mReg3g expression in areas of the 
gut, but histological gut GVHD was limited compared to the skin, liver and lungs 
which displayed severe signs of disease 
• Better characterisation of P2X7, and GVHD impact, in the gut, skin, liver and lung in 
this humanised mouse model will allow for a more thorough analysis when trialling 
therapeutics to reduce or prevent GVHD 
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Figure 1: NSG mice injected with hPBMCs contain circulating human T cells and develop 
clinical GVHD. (a-e) NSG mice were injected i.p. with 10 x 106 hPBMCs or PBS on day 0. 
(a-d) Blood from all mice (week 3) was examined by flow cytometry for the presence of 
leukocytes. (a) Cells were gated as shown and the proportion of (b) hCD45+ or (c) hCD3+ T 
cells of hCD45+ cells, and (d) hCD4+ or hCD8+ cells of hCD3+ T cells determined. All mice 
were monitored 3 times a week for up to 10 weeks for (e) weight loss, (f) clinical score and 
(g) survival. (b-f) Data represented as group mean ± standard deviation. (g) Data represented 
as percent survival. (b-d) Symbols represent individual mice.  (b-g) n = 4, control mice; n = 
26 hu-PBMC-NSG mice. Significance of hu-PBMC-NSG versus control determined by (b, d) 
Student’s t-test, (e, f) repeated measures ANOVA or (g) log-rank (Mantel-Cox). *P < 0.05, 
**P < 0.01, ***P < 0.001. Non-significant values not shown. 
Figure 2: hu-PBMC-NSG mice engraft hCD45+ hCD3+ T cells in the spleen and display 
circulating hIFNγ. (a-d) Spleens from control and hu-PBMC-NSG mice (endpoint) were 
examined by flow cytometry. (a) Cells were gated as shown and the proportion of (b) 
hCD45+ or (c) hCD3+ T cells of hCD45+ cells, and (d) hCD4+ or hCD8+ cells of hCD3+ T 
cells determined. Relative expression of (e) mP2rx7, and (f) hP2RX7 and hP2RX7B in spleen 
at endpoint were determined by qPCR. (g) Serum hIFNγ at endpoint was measured by 
ELISA. (b-g) Data represented as group mean ± standard deviation; symbols represent 
individual mice (n = 2-4, control mice; n = 8–26, hu-PBMC-NSG mice). Significance of hu-
PBMC-NSG versus control determined by Student’s t-test; *P < 0.05, ***P < 0.001. Non-
significant values not shown. 
Figure 3: hu-PBMC-NSG mice engraft gut-homing T cells but do not develop histological 
signs of gut GVHD. Human CD4+ or CD8+ T cells from (a) human blood and (b) mouse 
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blood (week 3) or (c) spleens (endpoint) from hu-PBMC-NSG mice were examined for 
integrin β7 expression by flow cytometry. (d) Sections of duodenum, jejunum, ileum and 
colon from mice at endpoint were examined for histological evidence of GVHD. (a-c) Data 
represented as group mean ± standard deviation; symbols represent individual (a) humans (n 
= 7) or (b, c) mice (n = 16). Significance determined by Student’s t-test; **P < 0.01, ***P < 
0.001. (d) Scale bar represents 100 µm. 
Figure 4: mP2rx7 and mReg3g expression is upregulated in the duodenum and ileum of hu-
PBMC-NSG mice while gut length is unaltered. (a) Lower gastrointestinal tract (duodenum 
to colon inclusive) (left panel), small intestine (middle panel) and colon (right panel) length 
was measured at endpoint. (b-f) Relative expression of (b) mP2rx7, and (c) hP2RX7 and 
hP2RX7B, (d) mP2rx1, (e)  mP2rx4 and (f) mReg3g in gut sections (as indicated) at endpoint 
were determined by qPCR. (g) Serum REG3γ at endpoint was measured by ELISA. (a-g) 
Data represented as mean ± standard deviation; symbols represent individual mice (n = 4, 
control mice; n = 7–15, hu-PBMC-NSG mice). (g) Dashed lines represent two SDs from 
control mean. Significance of hu-PBMC-NSG versus control determined by Student’s t-test. 
*P < 0.05, **P < 0.01, ***P < 0.001. Non-significant values not shown.  
Figure 5: hu-PBMC-NSG mice engraft skin-homing T cells and develop cutaneous GVHD, 
including ear swelling. Human CD4+ or CD8+ T cells from (a) human blood and (b) blood 
(week 3) or (c) spleens (endpoint) from hu-PBMC-NSG mice were examined for cutaneous 
lymphocyte antigen (CLA) expression by flow cytometry. (d) Sections of flank skin and ears 
at endpoint were examined for histological evidence of GVHD. (e) Ear swelling in all mice 
was measured using a spring loaded calliper three times a week for 10 weeks or until 
endpoint. (f-i) Relative expression of (f) mP2rx7, (g) hP2RX7 and hP2RX7B, (h) mP2rx1 and 
(i) mP2rx4 in (f-i) skin or (f, g) ears at endpoint were determined by qPCR. (a-c, e-i) Data is 
represented as mean ± standard deviation; (a-c, f-i) symbols represent individual mice (n = 4, 
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control mice; n = 8–26 hu-PBMC-NSG mice). Significance of hu-PBMC-NSG versus control 
determined by Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001. Non-significant values 
not shown. (d) Scale bar represents 100 µm, black arrowheads indicate dermal-epidermal 
junction separation, red arrowheads indicate apoptotic keratinocytes, stars indicate areas with 
epidermal thickening. 
Figure 6: hu-PBMC-NSG mice develop hepatic GVHD with human T cells present in the 
liver. (a) Sections of liver were examined for histological evidence of GVHD. (b) hCD45+ 
(left) and hCD3+ (right) cells were examined in the liver by flow cytometry. (c, d) Relative 
expression of (c) mP2rx7, and (d) hP2RX7 and hP2RX7B in the liver at endpoint were 
determined by qPCR. (b-d) Data is represented as mean ± standard deviation; symbols 
represent individual mice (n = 4, control mice; n = 6–8, hu-PBM-NSG mice). Significance of 
hu-PBMC-NSG versus control determined by Student’s t-test. Non-significant values not 
shown. (a) Scale bar represents 100 µm. 
Figure 7: hu-PBMC-NSG mice develop histological evidence of lung GVHD. (a) Sections of 
lung from control and hu-PBMC-NSG mice were examined for histological evidence of 
GVHD. (b, c) Relative expression of (b) mP2rx7, and (c) hP2RX7 and hP2RX7B in lungs at 
endpoint were determined by qPCR. (b, c) Data is represented as mean ± standard deviation; 
symbols represent individual mice (n = 4, control mice; n = 8, hu-PBMC-NSG mice). 
Significance of hu-PBMC-NSG versus control determined by Student’s t-test. Non-
significant values not shown. (a) Scale bar represents 100 µm. 
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